Aurora Sheboygan Pricing: Ravulizumab Intravenous Solution 300 mg/3 ml at $776.93
Aurora Medical Center Sheboygan County offers a range of medical services, including the administration of specialized medications such as Ravulizumab Intravenous Solution. Ravulizumab, marketed under the brand name Ultomiris, is a monoclonal antibody used primarily to treat certain rare blood disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). The cost for a 300 mg/3 ml intravenous solution of Ravulizumab at Aurora Sheboygan is priced at $776.93, reflecting the center’s commitment to providing cutting-edge treatments while maintaining transparency in pricing.
What is Ravulizumab used for? – Ravulizumab is used to treat rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) by inhibiting the complement system to prevent the destruction of red blood cells.
How is Ravulizumab administered? – Ravulizumab is administered as an intravenous infusion, typically in a hospital or clinical setting, under the supervision of healthcare professionals.
What are the potential side effects of Ravulizumab? – Common side effects of Ravulizumab may include headache, upper respiratory tract infections, and nausea, while serious side effects can include infusion-related reactions and increased risk of infections.
How often is Ravulizumab administered? – The dosing schedule for Ravulizumab typically involves an initial loading dose followed by maintenance doses every eight weeks, depending on the specific condition being treated.
Is Ravulizumab covered by insurance? – Coverage for Ravulizumab varies by insurance provider and plan, so patients should consult with their insurance company to determine their specific coverage and potential out-of-pocket costs.
Why is Ravulizumab so expensive? – The high cost of Ravulizumab is attributed to its status as a biologic drug, the complexity of its development and manufacturing process, and its use in treating rare conditions with limited patient populations.
